KR20180116475A - 조직 보호 펩티드 및 이의 용도 - Google Patents

조직 보호 펩티드 및 이의 용도 Download PDF

Info

Publication number
KR20180116475A
KR20180116475A KR1020187030050A KR20187030050A KR20180116475A KR 20180116475 A KR20180116475 A KR 20180116475A KR 1020187030050 A KR1020187030050 A KR 1020187030050A KR 20187030050 A KR20187030050 A KR 20187030050A KR 20180116475 A KR20180116475 A KR 20180116475A
Authority
KR
South Korea
Prior art keywords
amino acid
peptide
disease
tissue protective
trauma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187030050A
Other languages
English (en)
Korean (ko)
Inventor
안토니 세라미
마이클 브린스
토마스 콜만
Original Assignee
아라임 파마슈티칼즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아라임 파마슈티칼즈, 인크. filed Critical 아라임 파마슈티칼즈, 인크.
Publication of KR20180116475A publication Critical patent/KR20180116475A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
KR1020187030050A 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도 Ceased KR20180116475A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70574105P 2005-08-05 2005-08-05
US60/705,741 2005-08-05
US70627605P 2005-08-08 2005-08-08
US60/706,276 2005-08-08
US83173706P 2006-07-18 2006-07-18
US60/831,737 2006-07-18
PCT/US2006/031061 WO2007019545A2 (en) 2005-08-05 2006-08-07 Tissue protective peptides and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187016750A Division KR20180067735A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197019568A Division KR20190084136A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20180116475A true KR20180116475A (ko) 2018-10-24

Family

ID=37728020

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020187030050A Ceased KR20180116475A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020177005579A Ceased KR20170027868A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020207016998A Ceased KR20200072568A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020137016015A Expired - Fee Related KR101713368B1 (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020187016750A Ceased KR20180067735A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020197019568A Ceased KR20190084136A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020087005373A Expired - Fee Related KR101626153B1 (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도

Family Applications After (6)

Application Number Title Priority Date Filing Date
KR1020177005579A Ceased KR20170027868A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020207016998A Ceased KR20200072568A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020137016015A Expired - Fee Related KR101713368B1 (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020187016750A Ceased KR20180067735A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020197019568A Ceased KR20190084136A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020087005373A Expired - Fee Related KR101626153B1 (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도

Country Status (25)

Country Link
US (7) US8071554B2 (en:Method)
EP (5) EP1924276A4 (en:Method)
JP (6) JP5274253B2 (en:Method)
KR (7) KR20180116475A (en:Method)
CN (2) CN101378772B (en:Method)
AU (1) AU2006278264B2 (en:Method)
BR (1) BRPI0614529A8 (en:Method)
CA (3) CA2618396C (en:Method)
DK (3) DK2594279T3 (en:Method)
EA (1) EA015672B1 (en:Method)
ES (3) ES2550055T3 (en:Method)
HU (3) HUE035793T2 (en:Method)
IL (3) IL189287A (en:Method)
IN (1) IN2014CN02050A (en:Method)
LT (2) LT2540309T (en:Method)
MX (3) MX2008001509A (en:Method)
NO (1) NO20081112L (en:Method)
NZ (1) NZ565937A (en:Method)
PL (3) PL2594279T3 (en:Method)
PT (3) PT2371855E (en:Method)
SG (2) SG10201805825SA (en:Method)
SI (3) SI2594279T1 (en:Method)
UA (1) UA100222C2 (en:Method)
WO (1) WO2007019545A2 (en:Method)
ZA (1) ZA201101890B (en:Method)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US9585932B2 (en) * 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
DK2594279T3 (en) 2005-08-05 2018-01-08 Araim Pharmaceuticals Inc Tissue-protecting peptides and uses thereof
BRPI0712063A2 (pt) * 2006-06-07 2011-12-20 Chugai Pharmaceutical Co Ltd tratamento de doenças isquêmicas usando eritropoietina
WO2008058942A2 (en) * 2006-11-13 2008-05-22 Charite - Universitätsmedezin Berlin Method of cell culture and method of treatment comprising a vepo protein variant
AU2014203195B2 (en) * 2008-01-22 2016-03-31 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
KR20190085187A (ko) * 2008-01-22 2019-07-17 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
AU2016203452B2 (en) * 2008-01-22 2018-02-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US9566349B2 (en) * 2010-10-14 2017-02-14 Rutgers, The State University Of New Jersey Intestinal peptide targeting ligands
US8791234B2 (en) * 2010-10-14 2014-07-29 Rutgers, The State University Of New Jersey Intestinal peptide targeting ligands
CN102180948A (zh) * 2011-03-03 2011-09-14 复旦大学附属中山医院 一种具有肾脏保护作用的短肽及其制备方法和应用
CN102212111B (zh) * 2011-05-05 2014-04-30 中国人民解放军第三军医大学 小分子多肽和小分子多肽脂质体及其运用
CA2843014C (en) * 2011-07-27 2020-01-21 Neumedicines, Inc. Use of il-12 to generate endogenous erythropoietin
US20140249573A1 (en) * 2011-09-20 2014-09-04 A.A. Cash Technology Ltd. Methods and devices for occluding blood flow to an organ
KR101148191B1 (ko) * 2011-09-27 2012-05-23 김후정 에리스로포이에틴-유래 펩타이드 및 그 용도
WO2013158871A1 (en) * 2012-04-20 2013-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of erythropoietin and derivatives for treating hypertension
US20160168199A1 (en) * 2013-07-17 2016-06-16 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN104744593A (zh) * 2013-12-25 2015-07-01 深圳先进技术研究院 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
KR20150130616A (ko) * 2014-05-13 2015-11-24 (주)케어젠 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도
CN105924504A (zh) * 2014-06-22 2016-09-07 马恒标 组织保护活性多肽sl14及其应用
CA3001065A1 (en) 2015-10-14 2017-04-20 Xiaoxi WEI Compositions and methods for reducing ice crystal formation
WO2017189988A1 (en) 2016-04-29 2017-11-02 Araim Pharmaceuticals, Inc. Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage
WO2018086732A1 (en) 2016-11-10 2018-05-17 Asc Regenity Ltd. Cosmetic formulations for topical applications containing erythropoietin-derived molecules
KR101965814B1 (ko) * 2017-02-27 2019-08-13 재단법인 대구경북과학기술원 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용
CN108503690B (zh) * 2017-02-28 2020-07-03 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
US11260101B2 (en) 2017-02-28 2022-03-01 Jinan University Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof
KR20200142521A (ko) * 2018-04-08 2020-12-22 브림 바이오테크놀로지, 인코퍼레이티드 Pedf-유래 짧은 펩타이드의 힘줄 치유에의 적용
KR102300060B1 (ko) 2018-06-12 2021-09-08 주식회사 엘지에너지솔루션 2열 터미널 구조의 pcb 다이렉트 커넥터
CA3112382A1 (en) 2018-09-10 2020-03-19 Cold Spring Harbor Laboratory Methods for treating pancreatitis
CN112390877B (zh) * 2019-08-16 2022-10-04 董红燕 Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用
CN118255845B (zh) * 2022-12-27 2025-07-11 上海瑞吉康生物医药有限公司 相分离逆转多肽的变体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5498694A (en) 1989-05-25 1996-03-12 La Jolla Cancer Research Foundation Peptides of the cytoplasmic domain of integrin
DE3924746A1 (de) 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6140120A (en) * 1993-02-12 2000-10-31 Board Of Trustees Of Leland Stanford Jr. University Regulated transcription of targeted genes and other biological events
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
AU712713B2 (en) * 1995-06-07 1999-11-11 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
AU4267297A (en) * 1997-09-11 1998-09-22 Regents Of The University Of California, The Method of alleviating neuropathic pain
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
KR100883232B1 (ko) * 1999-04-13 2009-02-10 케네쓰 에스 워렌 래보러토리즈 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능 조절법
WO2001083548A1 (en) * 2000-04-28 2001-11-08 Effector Cell Institute Novel derivative of cell chemotactic factor
KR100645843B1 (ko) * 2000-12-20 2006-11-14 에프. 호프만-라 로슈 아게 에리트로포이에틴 접합체
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
BR0207015A (pt) 2001-02-06 2004-07-06 Merck Patent Ges Mit Beschroen Eritropoientina modificada (epo) com imunogenicidade reduzida
CA2443373A1 (en) * 2001-04-04 2002-10-31 Genodyssee New polynucleotides and polypeptides of the erythropoietin gene
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
MXPA05000063A (es) 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
KR100478455B1 (ko) 2002-08-19 2005-03-22 삼성전자주식회사 전자렌지
MXPA05002617A (es) 2002-09-09 2005-09-08 Warren Pharmaceuticals Inc Eritropoyetinas de accion prolongada que mantienen la actividad protectora de tejidos de la eritropoyetina endogena.
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
CA2500715A1 (en) * 2002-10-03 2004-04-15 Epimmune, Inc. Hla binding peptides and their uses
JP2004305006A (ja) * 2003-04-01 2004-11-04 Japan Science & Technology Agency 人工調製肺サーファクタント
ES2354304T3 (es) * 2003-04-25 2011-03-11 The University Of Pittsburgh Células derivadas del músculo (mdcs) para promover y potenciar la regeneración y reparación de nervios.
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
CN1897959A (zh) 2003-09-29 2007-01-17 沃伦药品公司 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
WO2007010552A2 (en) 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US8329652B2 (en) 2005-05-10 2012-12-11 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
DK2594279T3 (en) * 2005-08-05 2018-01-08 Araim Pharmaceuticals Inc Tissue-protecting peptides and uses thereof
EP2109690B9 (en) 2007-11-29 2012-10-24 MOLECULAR HEALTH GmbH Eph-b4 specific sirna for reducing epo-induced tumor cell growth during anemia treatment in cancer patients, tissue protective erythropoietin receptor (nepor) and methods of use.
KR20190085187A (ko) 2008-01-22 2019-07-17 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
AU2009243187C1 (en) * 2008-04-28 2015-12-24 President And Fellows Of Harvard College Supercharged proteins for cell penetration
WO2011022056A2 (en) 2009-08-18 2011-02-24 Medical College Of Georgia Research Institute, Inc. PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF

Also Published As

Publication number Publication date
DK2371855T3 (en) 2015-09-21
IL261346A (en) 2018-10-31
ES2653864T3 (es) 2018-02-09
DK2594279T3 (en) 2018-01-08
BRPI0614529A2 (pt) 2011-08-09
IL239695A0 (en) 2015-08-31
JP6491621B2 (ja) 2019-03-27
SG10201805825SA (en) 2018-08-30
US10100096B2 (en) 2018-10-16
PL2371855T3 (pl) 2015-12-31
CA3079319A1 (en) 2007-02-15
CN101378772B (zh) 2013-12-04
JP6158235B2 (ja) 2017-07-05
NZ565937A (en) 2011-09-30
KR20080064800A (ko) 2008-07-09
SI2371855T1 (sl) 2015-11-30
IL189287A0 (en) 2008-06-05
EP1924276A2 (en) 2008-05-28
KR20130080481A (ko) 2013-07-12
EA200800536A1 (ru) 2009-02-27
JP2016196480A (ja) 2016-11-24
HK1127751A1 (en) 2009-10-09
CA2982909A1 (en) 2007-02-15
KR101713368B1 (ko) 2017-03-07
WO2007019545A3 (en) 2008-10-02
JP2020078317A (ja) 2020-05-28
KR20170027868A (ko) 2017-03-10
EP2594279A1 (en) 2013-05-22
KR101626153B1 (ko) 2016-06-01
CA2618396A1 (en) 2007-02-15
JP5918155B2 (ja) 2016-05-18
JP5274253B2 (ja) 2013-08-28
EP2540309A2 (en) 2013-01-02
US9340598B2 (en) 2016-05-17
US8071554B2 (en) 2011-12-06
KR20180067735A (ko) 2018-06-20
HUE026444T2 (en) 2016-05-30
JP2018134084A (ja) 2018-08-30
SG2014007868A (en) 2014-05-29
IN2014CN02050A (en:Method) 2015-05-29
JP2009508471A (ja) 2009-03-05
IL189287A (en) 2015-07-30
KR20190084136A (ko) 2019-07-15
CN101378772A (zh) 2009-03-04
PL2594279T3 (pl) 2018-03-30
ZA201101890B (en) 2012-12-27
AU2006278264B2 (en) 2012-12-06
SI2540309T1 (en) 2018-04-30
MX364100B (es) 2019-04-12
US20120142595A1 (en) 2012-06-07
AU2006278264A1 (en) 2007-02-15
EP2371855B1 (en) 2015-07-22
PT2594279T (pt) 2017-12-29
US20140323401A1 (en) 2014-10-30
WO2007019545A2 (en) 2007-02-15
MX2008001509A (es) 2008-04-04
SI2594279T1 (en) 2018-04-30
DK2540309T3 (en) 2018-01-08
LT2594279T (lt) 2018-01-10
BRPI0614529A8 (pt) 2016-07-12
EP2540309A3 (en) 2013-05-29
US8673861B2 (en) 2014-03-18
PT2540309T (pt) 2017-12-29
UA100222C2 (uk) 2012-12-10
KR20200072568A (ko) 2020-06-22
EP2594279B1 (en) 2017-11-22
ES2653790T3 (es) 2018-02-08
HUE035793T2 (en) 2018-05-28
CN103724418A (zh) 2014-04-16
PT2371855E (pt) 2015-11-03
US20190016769A1 (en) 2019-01-17
CN103724418B (zh) 2018-03-06
JP2015134772A (ja) 2015-07-27
JP2013126995A (ja) 2013-06-27
CA2618396C (en) 2018-02-27
US20160244498A1 (en) 2016-08-25
MX339613B (es) 2016-06-02
EA015672B1 (ru) 2011-10-31
ES2550055T3 (es) 2015-11-04
US20120264682A1 (en) 2012-10-18
EP2540309B1 (en) 2017-11-22
HUE035655T2 (en) 2018-05-28
US20090221482A1 (en) 2009-09-03
EP3363451A1 (en) 2018-08-22
EP2371855A1 (en) 2011-10-05
LT2540309T (lt) 2018-01-10
US8716245B2 (en) 2014-05-06
US20150152156A1 (en) 2015-06-04
NO20081112L (no) 2008-05-05
EP1924276A4 (en) 2009-07-22
PL2540309T3 (pl) 2018-03-30

Similar Documents

Publication Publication Date Title
KR101713368B1 (ko) 조직 보호 펩티드 및 이의 용도
AU2013201291B2 (en) Tissue protective peptides and uses thereof
AU2020201658A1 (en) Tissue protective peptides and uses thereof
HK1196622A (en) Tissue protective peptides and uses thereof
HK1185546B (en) Tissue protective peptides and uses thereof
HK1196622B (en) Tissue protective peptides and uses thereof
HK1127751B (en) Tissue protective peptides and uses thereof
HK1185546A (en) Tissue protective peptides and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A17-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A17-div-PA0104

E601 Decision to refuse application
PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601